AstraZeneca cancer combo fails in late-stage study

March 6, 2020

AstraZeneca announced that its combination treatment for a form of bladder cancer failed to meet the main goal of improving overall survival in patients with an advanced form of the disease in a Phase III study.

The DANUBE trial was testing Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer.

Imfinzi is approved for patients with locally advanced or metastatic bladder cancer previously treated with platinum-containing chemotherapy in 15 countries, including the United States. Tremelimumab is a human monoclonal antibody and potential new medicine that targets the activity of cytotoxic T-lymphocyte-associated protein 4. It is currently being tested in a clinical trial programm in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer.

Read the press release